VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Male or female, 18 years of age or older           │ Male or female, 18 years of age or older           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Study eye with clinically significant diabetic     │ Study eye with clinically significant diabetic     │     100 │
│ macular edema (DME) with central subfield          │ macular edema (DME) with central subfield          │         │
│ thickness ≥ 350µm on spectral domain OCT           │ thickness ≥ 350µm on spectral domain OCT           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Best corrected visual acuity (BCVA) of 20/50 to    │ Best corrected visual acuity (BCVA) of 20/50 to    │     100 │
│ 20/320 ETDRS equivalent (65 letters to 23 letters) │ 20/320 ETDRS equivalent (65 letters to 23 letters) │         │
│ in the study eye, with BCVA decrement primarily    │ in the study eye, with BCVA decrement primarily    │         │
│ attributable to DME                                │ attributable to DME                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment naïve, i.e., no previous anti-VEGF       │ Treatment naïve, i.e., no previous anti-VEGF       │     100 │
│ treatment in the study eye or no anti-VEGF         │ treatment in the study eye or no anti-VEGF         │         │
│ treatment in the 45 days prior to study enrollment │ treatment in the 45 days prior to study enrollment │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In the investigator's opinion, the subject still   │ In the investigator's opinion, the subject still   │     100 │
│ has significant intraretinal fluid with room for   │ has significant intraretinal fluid with room for   │         │
│ improvement in both macular edema and BCVA         │ improvement in both macular edema and BCVA         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Willing and able to return for all study visits    │ Willing and able to return for all study visits    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able to meet the extensive post-op evaluation      │ Able to meet the extensive post-op evaluation      │     100 │
│ regimen                                            │ regimen                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Understands and signs the informed consent form    │ Understands and signs the informed consent form    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active proliferative diabetic retinopathy (PDR) in │ Active proliferative diabetic retinopathy (PDR) in │     100 │
│ the study eye such as NVE, NVD, vitreous           │ the study eye such as NVE, NVD, vitreous           │         │
│ hemorrhage, or neovascular glaucoma                │ hemorrhage, or neovascular glaucoma                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Focal laser photocoagulation or                    │ Focal laser photocoagulation or                    │     100 │
│ intravitreal/periocular steroids of any type in    │ intravitreal/periocular steroids of any type in    │         │
│ the study eye within the last 90 days prior to     │ the study eye within the last 90 days prior to     │         │
│ study enrollment                                   │ study enrollment                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A history of intravitreal anti-VEGF injection of   │ A history of intravitreal anti-VEGF injection of   │     100 │
│ any type in the study eye within the last 45 days  │ any type in the study eye within the last 45 days  │         │
│ prior to study enrollment                          │ prior to study enrollment                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of rhegmatogenous retinal detachment,      │ History of rhegmatogenous retinal detachment,      │     100 │
│ retinal tear(s), or traction retinal detachments   │ retinal tear(s), or traction retinal detachments   │         │
│ in the study eye                                   │ in the study eye                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Epiretinal membrane and/or vitreomacular traction  │ Epiretinal membrane and/or vitreomacular traction  │     100 │
│ in the study eye as determined by the central      │ in the study eye as determined by the central      │         │
│ reading center                                     │ reading center                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous pars plana vitrectomy in the study eye    │ Previous pars plana vitrectomy in the study eye    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any intraocular surgery in the study eye within    │ Any intraocular surgery in the study eye within    │     100 │
│ the last 90 days prior to study enrollment         │ the last 90 days prior to study enrollment         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ YAG laser treatment in the study eye in last 30    │ YAG laser treatment in the study eye in last 30    │     100 │
│ days prior to study enrollment                     │ days prior to study enrollment                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other ocular pathologies that in the               │ Other ocular pathologies that in the               │     100 │
│ investigator's opinion would interfere with the    │ investigator's opinion would interfere with the    │         │
│ subject's vision in the study eye                  │ subject's vision in the study eye                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic or recurrent uveitis                       │ Chronic or recurrent uveitis                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ongoing ocular infection or inflammation in either │ Ongoing ocular infection or inflammation in either │     100 │
│ eye                                                │ eye                                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A history of cataract surgery                      │ A history of cataract surgery                      │     100 │
│ complications/vitreous loss in the study eye       │ complications/vitreous loss in the study eye       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Congenital eye malformations in the study eye      │ Congenital eye malformations in the study eye      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A history of penetrating ocular trauma in the      │ A history of penetrating ocular trauma in the      │     100 │
│ study eye                                          │ study eye                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mentally handicapped                               │ Mentally handicapped                               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant female, as determined for women less than │ Pregnant female, as determined for women less than │     100 │
│ 60 years old by a positive urine pregnancy test    │ 60 years old by a positive urine pregnancy test    │         │
│ during the screening window                        │ during the screening window                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Nursing female                                     │ Nursing female                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Currently participating in any other clinical      │ Currently participating in any other clinical      │     100 │
│ research study                                     │ research study                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindication to the study medication           │ Contraindication to the study medication           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled hypertension defined as systolic      │ Uncontrolled hypertension defined as systolic >180 │      99 │
│ \>180 mmHg or \> 160 mmHg on 2 consecutive         │ mmHg or > 160 mmHg on 2 consecutive measurements   │         │
│ measurements or diastolic \> 100 mmHg on optimal   │ or diastolic > 100 mmHg on optimal medical regimen │         │
│ medical regimen                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening HgA1c blood test \> 10.0                 │ Screening HgA1c blood test > 10.0                  │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ High myopia in the study eye, with a spherical     │ High myopia in the study eye, with a spherical     │      99 │
│ equivalent of \>8.00D at screening                 │ equivalent of >8.00D at screening                  │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                              │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years              │ Male or female, 18 years of age or older           │      41 │
├────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intra-Ocular Pressure (IOP) is under control   │ Intra-Ocular Pressure (IOP) is under control       │      58 │
│ (i.e., IOP                                     │ (i.e., IOP ≤ 25 mm in the study eye) and study eye │         │
│                                                │ is not receiving any IOP lowering drops            │         │
├────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ≤ 25 mm in the study eye) and study eye is not │ Intra-Ocular Pressure (IOP) is under control       │      74 │
│ receiving any IOP lowering drops               │ (i.e., IOP ≤ 25 mm in the study eye) and study eye │         │
│                                                │ is not receiving any IOP lowering drops            │         │
╘════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                              │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ ≤ 25 mm in the study eye) and study eye is not │ Intra-Ocular Pressure (IOP) is under control       │      74 │
│ receiving any IOP lowering drops               │ (i.e., IOP ≤ 25 mm in the study eye) and study eye │         │
│                                                │ is not receiving any IOP lowering drops            │         │
╘════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 95.41176470588235
OverAll Ratio: 97.20588235294117
